IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), announced today that its
second quarter 2015 financial results will be released after the market
closes on Wednesday, August 5, 2015. Following the release, Aerie will
host a live conference call and webcast at 5:00 p.m. Eastern Time to
discuss the Company’s financial results and provide a general business
The live webcast and a replay may be accessed by visiting Aerie’s
website at http://investors.aeriepharma.com.
Please connect to the Company’s website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (888)
734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live
conference call. The conference ID number for the live call is 86313347.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 86313347.
The telephone replay will be available until August 12, 2015.
About Aerie Pharmaceuticals
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. The Company is currently conducting a Phase 3 registration trial in
the United States named Rocket 2, where the primary efficacy endpoint is
to demonstrate non-inferiority of IOP lowering for Rhopressa™ compared
to timolol, along with a Phase 3 registration safety-only trial, named
Rocket 3, in Canada. The Company recently completed its initial Phase 3
registration trial, named Rocket 1, the three-month efficacy results of
which were initially reported in April 2015, and expects to commence a
fourth Phase 3 registration trial, named Rocket 4, in the third quarter
of 2015. The Company also completed in 2014 a Phase 2b clinical trial in
which Roclatan™ met the primary efficacy endpoint, demonstrating the
statistical superiority of Roclatan™ to each of its components, and
plans to commence the first Phase 3 registration trial for Roclatan™,
named Mercury 1, in the third quarter of 2015.
Powered by WPeMatico